안지오다이나믹스(ANGO) 2027 회계연도 1분기 실적 발표 컨퍼런스 콜: 의료기술 매출 13.2% 증가

핵심 요약

• 앤지오다이내믹스(AngioDynamics)는 메드텍(Med Tech) 매출이 3,990만 달러로 전년 동기 대비 13.2% 성장한 데 힘입어 2027 회계연도 1분기 매출이 전년 동기 대비 6.9% 증가한 8,090만 달러를 기록했다고 발표했다.
• 메드텍 비중은 전년 동기의 47%에서 상승해 전체 매출의 49%에 달했다. 경영진은 2027 회계연도 동안 해당 사업 부문이 회사 매출의 과반을 차지할 것으로 예상하고 있다.
• 오리온(Auryon) 매출은 1,890만 달러로 14.7% 증가하며 21분기 연속 전년 동기 대비 두 자릿수 성장을 기록했다.
• 나노나이프(NanoKnife) 매출은 프로브 성장률 24.1%, 장비(Capital) 매출 성장률 53.5%에 힘입어 29% 증가한 830만 달러를 기록했다. 경영진은 소모품과 전립선 시술 건수를 사업의 핵심 지표로 꼽았다.
• GAAP 순손실은 710만 달러(주당 0.17달러)로 축소되었으며, 조정 EBITDA는 220만 달러에서 500만 달러로 증가했다.
• 회사는 2027 회계연도 매출 가이던스 3억 3,600만~3억 4,100만 달러, 조정 EBITDA 가이던스 1,300만~1,600만 달러를 유지했다.

주요 재무 데이터

사업 및 영업 실적

오리온(Auryon)

오리온은 14.7% 증가한 1,890만 달러의 매출을 올렸다. 이러한 성장은 병원 및 개원의 기반 검사실 전반에서의 고객 확대와 CE 마크 승인에 따른 해외 도입에 힘입은 결과다.

경영진은 해당 플랫폼이 시장 점유율을 지속적으로 확대하고 있다고 밝히며, 스텐트 재협착 치료 능력과 무릎 위·아래 시술이 모두 가능하다는 점을 강조했다. AMBITION BTK 임상연구 피험자 모집도 계속 진행 중이다.

기계적 혈전제거술

앤지오백(AngioVac)과 알파백(AlphaVac)의 합산 매출은 6.7% 증가한 1,200만 달러를 기록했다.

알파백 매출은 전년 동기 대비 37.4%, 전분기 대비 6.4% 증가한 450만 달러를 기록했다. 앤지오백 매출은 전년 동기 대비 5.9% 감소한 750만 달러였으나, 전분기 대비로는 9.1% 증가했다.

경영진은 이러한 모멘텀의 원인을 영업력 강화, 신규 의사 도입, 경쟁사 제품에서의 전환으로 꼽았다. 알파리턴(AlphaReturn) 혈액 관리 시스템 IDE 연구 및 앤지오백 우심장 감염성 심내막염 IDE 연구의 피험자 등록도 호조를 유지했다.

나노나이프(NanoKnife)

나노나이프 매출은 29% 증가한 830만 달러를 기록했다. 프로브 매출은 24.1% 증가했고 장비 매출은 53.5% 상승했다. 회사는 분기 기준 역대 최대 전립선 시술 건수를 기록했다.

경영진은 장비 매출이 분기별로 고르지 않을 수 있다고 주의를 당부하며, 소모품 사용량이 근본적인 수요를 측정하는 더 중요한 지표라고 설명했다. 미국 내 성장은 대학병원이 아닌 일반 병원으로의 도입을 포함해 주로 전립선암 시술에서 비롯되고 있다.

회사는 팔메토 MAC(Palmetto MAC)의 긍정적인 결정에 따라 더 넓은 범위의 보험 급여 적용을 추진하고 있다. 또한 FDA는 전립선비대증(BPH) 치료에 대한 나노나이프 평가 연구인 RELIEF 임상시험을 승인했으며, 경영진은 이 시장 기회가 약 19억 달러 규모에 달할 것으로 추정하고 있다.

경영진 교체

에릭 혼로스(Eric Honroth)가 제임스 클레머(James Clemmer)의 뒤를 이어 11월 2일 자로 사장 겸 최고경영자(CEO)로 취임한다. 혼로스는 최근 게팅게(Getinge)의 라이프사이언스 부문 글로벌 사장을 역임했으며, 이전에는 게팅게의 12억 달러 규모 북미 사업을 이끌었다.

경영진 가이던스

경영진은 연간 기준으로 플러스(+) 영업활동 현금흐름을 계속 기대하고 있다. 연구개발비 지출은 나노나이프의 전립선비대증(BPH) 분야 진출 가능성에 대한 투자를 포함해 매출의 약 10%를 목표로 하고 있다.

회사는 현재 여건을 바탕으로 2027 회계연도 관세 영향이 2026 회계연도와 대동소이할 것으로 예상하면서도 상황이 가변적이라는 점을 덧붙였다.

리스크 및 주요 점검 사항

• 1분기 매출총이익률은 120만 달러의 관세 환급 혜택을 받았다. 이 혜택을 제외한 매출총이익률은 57.8%로, 공시된 59.4%와 차이가 있다.
• 경영진은 비용 상승의 회계적 영향으로 인해 상반기 매출총이익률이 하반기보다 더 높을 것으로 예상하고 있다.
• 나노나이프 장비 매출은 본질적으로 분기별 기복이 있으며, 사용량은 장비 시스템, 의사의 숙련도, 지역별 보험 급여 여건에 따라 차이가 난다.
• 최근 성과에도 불구하고 전국적으로 일관된 나노나이프 보험 급여 체계는 아직 확보되지 않았다.
• 앤지오백은 전분기 대비 매출이 개선되었음에도 불구하고 전년 동기 대비 비교 기준이 높았던 부담을 안고 있다.
• 회사는 이번 분기 동안 1,530만 달러의 영업 현금을 사용했다. 경영진은 회계연도 2분기와 3분기에는 현금 지출이 줄어들고, 4분기에 가장 강력한 현금 창출 능력을 보일 것으로 예상한다.

애널리스트 Q&A 주요 내용

• 나노나이프 가동률: 경영진은 신규 시스템 설치가 소모품 성장을 뒷받침할 것이지만, 적용 확대 속도는 계정마다 다르다고 설명했다. 자본 접근성, 의사 교육, 환자 선별, 보험 급여 모두 시술 성장에 영향을 미친다.
• 기계적 혈전제거술 확장: 영업 신규 채용 인력에 대한 교육이 완료되었으며, 추가 병원 재고 확보, 의사 도입, 경쟁사 제품에서의 전환을 통해 실적에 기여하고 있다. 경영진은 알파백이 계속해서 주요 성장 동력이 될 것으로 예상한다.
• 나노나이프 계절성: 회계연도 4분기가 통상 가장 견조한 분기인 반면, 3분기는 일반적으로 가장 저조하다. 경영진은 소모품 매출의 전분기 대비 감소에도 불구하고 1분기 전립선 시술 건수가 4분기를 상회했다고 밝혔다.
• 매출총이익률 동인: 관세 환급 외에도 제품 가격 정책, 메드텍 제품의 비중 확대, 코스타리카 관련 비용 절감이 이익률 개선을 뒷받침했다.
• RELIEF 및 BPH: 파일럿 프로그램은 전립선비대증(BPH) 조직에 대한 나노나이프의 효과를 평가하고 사업적 타당성을 검증하는 데 기여할 것이다. 경영진은 현재 이 프로그램으로 인해 연구개발비 지출이 매출의 약 10% 목표를 초과할 것으로 예상하지는 않는다.

실적발표 컨퍼런스 콜 전문

전체 실적 발표 컨퍼런스 콜 녹취록

경영진 발표

Operator

Good morning, and welcome to the AngioDynamics Fiscal Year 2027 First Quarter Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. The news release detailing AngioDynamics' fiscal 2027 first quarter results was issued earlier this morning and is available on the company's website. This conference call is also being broadcast live over the Internet at the Investors section of the company's website at www.angiodynamics.com. A webcast replay of the call will be available at the same site approximately 1 hour after the end of today's call. Before we begin, I'd like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings and gross margin for the fiscal year 2027 as well as trends that may continue.

Management encourages you to review the company's past and future filings with the SEC, including, without limitation, the company's Forms 10-Q and 10-K, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements. The company will also discuss certain non-GAAP financial measures during this call. Management uses these measures to establish operational goals and review operational performance and believes that these measures may assist investors in analyzing the underlying trends in the company's business over time. Investors should consider these non-GAAP measures in addition to, not a substitute for or as superior to financial reporting measures prepared in accordance with GAAP.

A slide package offering insight to the company's financial results is also available in the Investors section of the company's website under Events and Presentations. This presentation should be read in conjunction with the press release discussing the company's operating results and financial performance during this morning's conference call. Unless otherwise noted, all comparisons will be the first fiscal quarter of 2027 versus the first fiscal quarter of 2026. Now, I would like to turn the call over to Jim Clemmer, AngioDynamics' President and Chief Executive Officer. Mr. Clemmer?

James Clemmer

Thank you, operator. Good morning, everyone, and thank you for joining us for AngioDynamics' Fiscal 2027 First Quarter Earnings Call. Joining me today is Steve Trowbridge, AngioDynamics' Executive Vice President and Chief Financial Officer. Before I get into our results, I want to start with an important update. Our Board has completed a comprehensive search for my successor. I am pleased to share that Eric Honroth will be joining us as President and Chief Executive Officer, effective November 2. Eric brings more than 20 years of leadership experience in medical devices and life sciences. He most recently served as Global President, Life Science at Getinge. And before that, he led Getinge's $1.2 billion North American business, where he accelerated growth, delivered sustained revenue gains and strengthened operational performance.

His career spans the cardiovascular, endovascular, urology and oncology markets with senior leadership roles at Abbott Vascular, Becton, Dickinson, CareFusion and Boston Scientific. That combination is exactly what our Board was looking for. Someone who's driven real growth and profitability in large, complex organizations and who knows our markets firsthand. I am confident that he's the right person to build upon the foundation that we've put in place, and I'll remain closely involved to make sure that we have a smooth transition. I want to thank our Board, our search committee and everyone across this organization who helped to make this happen. Now, moving on to results. We grew total revenue by approximately 7%, led by strength in our Med Tech segment, which grew more than 13%.

That's clear evidence that the strategy guiding our transformation over the past several years keeps paying off. As a result, Med Tech now represents approximately 49% of our total revenue, and that mix shift is only gaining momentum as we move through the year. Starting with Auryon, which remains one of the most consistent growth engines in this business. This quarter marked our 21st consecutive quarter of double-digit year-over-year growth. We're taking share across both the hospital and office-based laboratory settings with international adoption building as well. We're also advancing enrollment in our AMBITION BTK study, which we believe will support the long-term clinical case for Auryon below the knee.

Turning to mechanical thrombectomy. We're also growing above market in this business, and the reason is simple. We have the most versatile product on the market and a commercial team that is executing at a high level, and we're taking share from our competitors. AlphaVac is building real momentum as more hospitals continue to adopt it. In addition, we're really pleased with the progression of our AlphaReturn blood management system IDE trial to further strengthen our position. AngioVac is working through a tougher comp right now, but the underlying demand for the product remains strong, and we expect it to return to more normal growth as the year progresses. Finally, NanoKnife continues to fundamentally change the landscape of men's health care by improving outcomes and preserving quality of life through an innovative procedure for men with intermediate-risk prostate cancer.

Reimbursement progress remains a key driver, including the positive MAC coverage decision that we received last quarter. And we're now working with additional regions with the goal of building towards consistent nationwide coverage. Physician interest and procedure volumes in prostate care remains strong. We also received FDA approval for our RELIEF study, which is evaluating NanoKnife for the treatment of BPH, a condition affecting millions of men and a market opportunity we estimate at approximately $1.9 billion, an important step in expanding where this technology can help patients. Our Med Device segment grew approximately 1%. This business remains a steady, reliable performer, providing the consistent cash flow that funds our investment in Med Tech platforms. Before I turn things over to Steve, I really want to thank our team.

The work happening across the company is reflected in this quarter's results and is driving future growth ahead. We compete in large, fast-growing markets, and we are positioned to win. Looking ahead, we have real catalysts in front of us, continued progress in AlphaReturn, expanding reimbursement coverage for NanoKnife and ongoing enrollment in our AMBITION BTK case study, each of which will create new opportunities. This all comes back to patients first. We believe people living with some of society's most challenging diseases deserve trusted solutions that deliver real care and better outcomes. When we deliver on that, we deliver value for everyone we serve from patients and physicians to our shareholders. Now, I'll turn it over to Steve to review the financials for the quarter.

Stephen Trowbridge

Thanks, Jim, and good morning, everybody. As always, before I begin, I'd like to direct everyone to the presentation on our Investor Relations website summarizing the key items from our quarterly results. Unless otherwise noted, all comparisons will be the first fiscal quarter of 2027 versus the first fiscal quarter of 2026. Company top line revenue performance was strong again in the quarter. Revenue increased 6.9% to $80.9 million, driven by growth across our Med Tech segments. Med Tech revenue was $39.9 million, a 13.2% increase. For the first fiscal quarter, our Med Tech platforms comprised 49% of our total revenue compared to 47% of total revenue a year ago, reflecting the ongoing shift in our business mix.

We remain on track for our Med Tech segment to comprise a majority of our overall revenue base during this fiscal year. Within our Med Tech segment, our Auryon platform contributed $18.9 million in revenue, growing 14.7% compared to last year. Auryon has now delivered double-digit year-over-year growth for 21 consecutive quarters. This above-market growth continues to be supported by our strategy to shift more of our atherectomy business towards the hospital side of care while we keep growing our customer base across both the hospital and OBL settings, along with ongoing international adoption following our CE Mark approval. We're confident in the long-term opportunity for our mechanical thrombectomy portfolio.

Combined AngioVac and AlphaVac sales were $12 million, an increase of 6.7% year-over-year. In the quarter, AlphaVac continued its strong trajectory, generating revenue of $4.5 million, representing a 37.4% year-over-year increase as well as growth of 6.4% sequentially. We're also pleased with the trajectory of AngioVac, which generated revenue of $7.5 million. And while this represented a 5.9% year-over-year decrease, AngioVac grew 9.1% sequentially. On the clinical front, we are encouraged by the ongoing progress in our AlphaReturn and AngioVac right-sided infective endocarditis IDE studies, both of which are seeing strong enrollment. Turning to NanoKnife. Total revenue was $8.3 million, an increase of 29%, with probes growing 24.1% and capital sales growing 53.5%.

Probe sales are primarily driven by demand for NanoKnife in prostate care, and we hit record procedure volumes during the quarter. Additionally, as systems are placed and new physicians and providers experience the improved patient outcomes our technology enables, we expect them to drive continued increases in probe utilization going forward. I will note that capital sales are always lumpy quarter-to-quarter, so we would not expect capital to grow at this rate going forward. We continue to view disposables as the bellwether for this business. In the first quarter, our Med Device segment increased 1.4% year-over-year with revenue of $41 million. This business generates consistent cash and profitability, allowing us to continue to invest in the growth of our Med Tech platforms. Now moving down the income statement.

Our gross margin for the first quarter of FY '27 was 59.4%, a 410 basis point increase from the first quarter of FY '26, driven primarily by favorable pricing and the ongoing revenue mix shift towards Med Tech, which is partially offset by the manufacturing transition and global inflation, all of which were in line with the company's expectations. Gross margin also benefited from tariff refunds received during the quarter. Absent that benefit, gross margin would have been 57.8%. We expect gross margin to be higher in the first half of fiscal 2027 than in the second half, and we remain on track for full year gross margins to be within our guided range of 54% to 55%. Total operating expenses, which include R&D, SG&A, amortization and nonrecurring items in the quarter, were $55.3 million, representing 68.4% of sales compared to $52.5 million or 69.4% of sales last year.

Turning to R&D. Our research and development expense was $8 million or 9.9% of sales compared to $6.4 million or 8.5% of sales a year ago. We remain committed to investing in R&D initiatives to support the long-term growth of our Med Tech segment, and we're targeting approximately 10% of sales going forward. SG&A expense for the first quarter of FY '27 was $42.5 million, representing 52.5% of sales compared to $40.7 million or 53.7% of sales a year ago. On a GAAP basis, our net loss for the first quarter was $7.1 million or a loss per share of $0.17 compared to a net loss of $10.9 million or a loss per share of $0.26 a year ago. Our adjusted net loss for the first quarter of FY '27 was $1.8 million or an adjusted loss per share of $0.04 compared to an adjusted net loss of $4.2 million or an adjusted loss per share of $0.10 in the first quarter of last year.

Adjusted EBITDA in the first quarter of FY '27 was $5 million compared to adjusted EBITDA of $2.2 million in the first quarter of '26. Touching briefly on tariffs. Tariff-related expenses were $0.9 million during the quarter compared to $1.7 million for the prior year quarter. This is in line with our expectations. Additionally, we did receive $1.2 million of tariff refunds during the quarter, resulting in a net tariff benefit of about $400,000. Turning to cash. In the first quarter, the company used $15.3 million of cash from operations, in line with our expectations. We ended the quarter with $34 million in cash, and we maintained a strong debt-free balance sheet. We also remain on track to generate positive cash flow from operations for the full fiscal year.

Turning to guidance. For fiscal '27, we continue to anticipate net sales to be in the range of $336 million to $341 million, representing growth of between 5% and 6.5% over fiscal '26 revenue of $320.2 million. Within each of our businesses, we expect Med Tech net sales to grow 12% to 15% year-over-year, and we expect Med Device sales to be roughly flat. For fiscal '27, we expect gross margin to be in the range of 54% to 55%. We expect adjusted EBITDA to be in the range of $13 million to $16 million. And finally, we expect adjusted loss per share in the range of $0.29 to $0.24. We expect the impact from tariffs to be broadly similar to fiscal '26 based on our current view of the tariff situation, but this remains dynamic and clearly subject to change. So, with that, I'll turn it back to Jim.

James Clemmer

Thanks, Steve. Before we close, I'd like to say a word about our leadership transition. Leading AngioDynamics has been the privilege of my career, and I'm incredibly proud of what our team has built together over the past 10 years. Together, we set a clear direction, built a strategy to transform this company and created a robust product portfolio that competes and wins in large important markets. It has not been easy, but this team has done it, and I'm very confident that our strength will carry forward. I have full confidence in Eric and in our organization's ability to keep executing at a high level through this transition. With that, operator, let's open the line for questions.

Operator

[Operator Instructions] Our first question comes from the line of Frank Takkinen with Lake Street Capital Markets.

질의응답

Frank Takkinen

Congrats on the progress and the new CEO appointment. On NanoKnife, I'd like to follow up on how do you think about once the equipment is placed and the time line to really scaling to a higher utilization rate. Obviously, fiscal Q4 had a really nice placement quarter and then you had a nice placement quarter in fiscal Q1 again. How should we think about when these systems might start to really contribute to the disposables business and that ramp-up expectation?

Stephen Trowbridge

Frank, this is Steve. Thanks for the question. So, I think it is -- the capital placement is a good way to think about driving NanoKnife, but we think that the better way to think about it is disposable growth. As we've talked about before, we've got a number of different placement models with NanoKnife, particularly in the prostate space. We're continuing to sell systems. We're also placing systems during the quarter, getting them in the hands of urologists. As we've said in the past, we don't want access to capital to be a governor on whether or not a urologist chooses NanoKnife for their practice. So, we've been very pleased with the pace of capital sales that we've seen over the course of the last 6, 8 quarters, as we've talked about.

You're right, Q4 was a very strong capital quarter. Q1 was another strong capital sales quarter. But we think that the right way to look at this business is the disposable sales. And we've been really pleased with the trajectory of the disposable sales growth that we've seen sequentially as well as year-over-year. So, yes, utilization is a good way to think about it. But utilization is going to be variable from system to system, depending upon where we place it, if it's going into a system that has had experience with NanoKnife in the past. As Jim talked about, there's variability in the pace of adoption based upon reimbursement in that particular area. We've been very pleased with what we've seen since we got the CPT I code and certainly with the Palmetto MAC decision that we talked about last quarter.

So, all of that is trending in the right direction. We think they're all showing very healthy signs for NanoKnife, starting with capital sales, but more importantly, looking at those disposable sales.

Frank Takkinen

Very helpful. Maybe on mechanical thrombectomy, I know we've talked about in the past some of the commercial enhancements you guys have implemented over the last few quarters. Maybe an update on some of those and whether or not those were kind of drivers in the quarter or if we're still waiting for some of the new heads to start contributing and we could see that as a second half contribution in the mechanical thrombectomy business.

Stephen Trowbridge

Yes, Frank, we expect mechanical thrombectomy to continue to grow. As we've talked about coming into this year, we're really excited about the combined AngioVac, AlphaVac business together. We think AngioVac is a little bit more niche right now. We expect that to be kind of in the single-digit growth, and we expect AlphaVac to really be driving that growth. We're definitely seeing the contributions from some of those changes that we made in the commercial organization. I expect those to continue. We're also just seeing continued enthusiasm from physicians who have got their hands on our product. As Jim said in the past, we really believe we've got the best product out there. And the more that we can get that product in the hands of physicians, they're going to choose AlphaVac for PE, they're going to choose AngioVac for those cases where AngioVac is the right product line.

So, yes, I expect to see continued benefits coming from all of the changes we're making in the commercial organization. But as we continue to just get more products in the hands of physicians, we expect that to also be a catalyst for growth. We mentioned in the prepared remarks, we're really excited about the pace of our AlphaReturn IDE enrollment to add blood return as another option to this product line. So, the continued development of the products, the line extensions, getting more people time in the sales organization and just getting more products in the hands of physicians are all going to continue to contribute to that growth over the course of this year.

Frank Takkinen

Very helpful. And then if I could just squeeze one more in, maybe related to cash usage. Obviously, fiscal Q1 is your highest cash usage quarter of the year. However, I think if you look back at last year, you used a little bit less cash on a little bit less revenue and this year, a little more revenue, but a little more cash usage. Can you maybe talk about some of the moving pieces related to that? And then maybe how we should think about cash generation through the end of the year?

Stephen Trowbridge

Yes. In general, I wouldn't say that there was a very big difference in this quarter versus where we've been historically. Q1 is always the largest utilization of cash quarter for us, and that comes from things like incentive compensation, sales compensation that gets paid in the quarter, tariffs are something new that's been added in the last 2 years. So, in general, you should think of cash utilization as being pretty consistent historically. So, what that means is expect Q1 to be the largest utilization, expect Q2 and Q3 to not have that level of utilization. Sometimes we generate a little bit of cash, maybe it's flat Q2 and Q3 with then Q4 being the largest generation quarter moving forward. I would expect that same cadence to continue this year. And then as we mentioned, we expect to be generating positive cash flow for -- from operations for this full fiscal year.

Operator

Our next question comes from the line of John Young with Canaccord Genuity.

John Young

Congratulations on the quarter. And Jim, congratulations again on the past 10 years and best wishes for your retirement. I also wanted to just talk about the mechanical thrombectomy business with you guys. Any color just on the number of new accounts that you opened in the quarter and how we should think about growth in this quarter from new accounts versus existing accounts? And have you been able to take any advantage of kind of disruptions that continue to occur in this space?

James Clemmer

John, good question. So, we measure new business through different angles here in this space through new competitive conversions through doctors who have come online to use it as they go up kind of the same-store sales approach. We measure how many hospitals put us through their value analysis process and get us into stock as well on the shelf next to maybe competitive products. So, each of those are trending in the right direction. The sales force additions we talked to you about we made earlier this year. The people are now trained up to speed, and they're contributing to each of those things. So, we have more doctors coming on using our device, more doctors using it in the same accounts and then more people who have it in stock on the shelf.

So, we're really pleased. We measure each of those very carefully and building up to what we hope will be the AlphaReturn project getting on label early next calendar year. As Steve mentioned earlier, we're pleased with the pace of enrollment, and we expect that to come on. That will just take that one more hurdle that the marketplace has for us. But we're managing our company, John. We watch the market really carefully. We've got good competitors in the space, as you know. And there's been disruption at those competitors. That we can't control, we watch, but we want to make sure we're the best angio that we can be. So, we continually build upon how we make our company better, what we bring to the physicians as a value prop better. And we'll monitor the disruption in other places. but we think we're going to win on our game as well, irrespective of our competitors.

John Young

Okay. That's great to hear. And then just on NanoKnife disposables in the quarter, down 20% from the last May quarter sequentially. Is that higher than seasonality of just a larger base of business now? Was there stocking in the last fiscal quarter? And maybe how did the results compare to your internal expectations? And can you just talk about any differences you're seeing in the business on the disposable side between sell-in and sell-through?

Stephen Trowbridge

Yes, John, thanks for the question. We're really excited about the trajectory we're seeing with NanoKnife. And this business is a little bit more mature than some of the other growth businesses. So, there is seasonality that you're going to see. Q4 for us is always our highest quarter. It's pretty typical in the Med Device business, you see that. So, we weren't expecting that we were going to see growth off of where we ended Q4. With your question to was there stocking and the throughput I don't think that, that's a material piece that we're seeing here. There's always going to be fluctuations in terms of selling and using. In the growth business, we want to be selling ahead of the curve. We want to make sure that those products are on the shelf for physicians so that they can use it when those patients come in.

We track the procedure volume every month, and we've been seeing consistent records that we're setting in terms of prostate procedures every month. Q1, we had larger procedure volume than what we saw in Q4. So, you see those procedures upticking. I think that's the right way to think about the business. So, there is going to be a little bit of seasonality, Q4 being the highest quarter, usually Q1 a little bit down from Q4. Usually, Q2 is a step-up from Q1, with Q3 being our softest quarter because structurally, that includes December, January and February. So, it's kind of a tough structural quarter there. Put that aside, we're really excited about what we're seeing with NanoKnife, continued procedure growth new physicians that are coming on adopting this technology, physicians that have already adopted it, continuing to lean in and use it more.

Good decisions that we're seeing on the reimbursement front. Of course, it's not mission accomplished there yet. There's a lot of work for us to do to continue to make sure that there's consistent, reliable reimbursement across the country. But what we've seen so far has all been very positive.

John Young

Okay. Great. And then just one more, if I could. Just I understand the gross margins in the quarter benefited from tariffs, but even on the adjusted basis that you called out, what drove increases beyond that? Are there any other onetime versus just lasting benefits that you're seeing? And is Costa Rica fully contributing at this point and baked into the guidance?

Stephen Trowbridge

Yes. So gross margin, we were pleased with what we saw in Q1. And you had mentioned the tariffs. I do think the right way to think about gross margin is to probably take out that tariff refund that we saw in the quarter. We expect to continue to get more tariff refunds going forward. I just don't know when they're going to come in. So, that 57.8% as opposed to the 59%, I think that's the right way to think about it as a baseline. One of the things that we talked about historically is we do have a little bit of a structural impact on gross margin where the first half of the year is going to be a little bit higher than the back half. That's just the way that you account for the rising cost environment. So, that's why we said we still expect guidance for gross margin to come in the full year in that 54% to 55%.

But really to get to your question, yes, the underlying gross margin trajectory is very strong. We're seeing the benefit from price that we talked about, particularly in the device business and then that mix shift. So, as the Med Tech higher-margin products become a larger portion of our overall revenue base, we're seeing that continue to build in and drive gross margins. The benefit of Costa Rica is in what we're seeing. We've talked about the fact that we were able to accelerate some of those cost savings over the course of the last 6 quarters or so. So, you've seen that kind of starting to get into the base and that can be a nice catalyst as we continue to move forward. So, we like what we're seeing in gross margin, definitely. It's all part of the strategy that we put in place.

The long-term driver is going to be that mix shift that we're seeing the benefit for. You've got noise with tariffs. You got noise with some of the rising cost environment. But as you eliminate that, that gross margin accretion story is really taking hold.

Operator

Our next question comes from the line of Yi Chen with H.C. Wainwright.

Katherine Degen

This is Katie on for Yi. Looking at RELIEF, what does that program need to demonstrate for you to commit to a larger BPH program? Symptom improvement, durability, what are you guys looking for? And if it meets that threshold, would the next stage fit within your existing R&D spending framework or require a step-up?

Stephen Trowbridge

Yes. In terms of RELIEF and using NanoKnife to treat BPH, we're excited about that opportunity. One of the things that we've always talked about is the fact that our Med Tech product portfolio is made up of 3 legs to a stool there, and every one of those legs is a platform opportunity. So, we're really excited about the opportunity to take AngioVac and AlphaVac to go into PE and then maybe take AngioVac on to the left side, where we think we've got a right to win and can really address an unmet clinical need. We're excited about Auryon and how it can work in the peripheral, and we've talked about taking the steps to now take Auryon and go into a coronary space. NanoKnife and BPH is that potential platform opportunity for us. We're still in the early stages. I think it's important for us to do the work to understand how does NanoKnife impact the tissue when it comes to BPH.

Durability that you mentioned is going to be a question for us. I don't think our pilot study is going to answer the durability, but it's something that we're going to continue to be focused on as we build out the business case here. So, RELIEF is really an opportunity for us to do the early-stage work, take NanoKnife, start to build out that business case of moving into that longer-term platform opportunity into BPH. Sorry, just to answer your question on the R&D. We've talked about targeting around 10% of sales for R&D going forward, and that's inclusive of the growth that we expect to see, particularly driven by Med Tech over the course of our strategic planning horizon. So, I don't look right now as BPH is something that's going to dramatically change our overall P&L. We're looking to take all of our opportunities and kind of fit it within that 10% target that we have for R&D going forward.

Operator

[Operator Instructions] Our next question comes from the line of [Alan Simanski] with Freedom Broker.

Unknown Analyst

Congrats on a strong start to the year. Jim, congrats on the retirement and on everything you've built over the last 10 years, and welcome to Eric. I wanted to ask about 2 things, if that's okay. First on Auryon, as more peripheral cases move into office-based labs, has that changed how you go to market? I'm also curious whether those customers behave differently from hospital accounts. Are they more price sensitive? Or do they tend to be more loyal once they adopt it?

James Clemmer

It's a great question. So, I'll remind you, we launched Auryon in the marketplace in September of 2020. If you look back, that was 6 months after the COVID interruption, all of our lives affected. So, launching Auryon then required us to spend most of our initial launch with the office-based lab customers because many hospitals were kind of closed for business for new products. They had to deal with the pandemic challenges they had internally. So, we got a lot of experience out of the gate building our business around the office-based lab customer, learned what's important to them and how we grew that business very rapidly. So, we understand that marketplace. A lot of the clinical needs are the same in the hospital or in the OBLs.

Economically, it's a little different story. So, a couple of years ago, when the hospitals more or less reopened for business, again, we talked to you about our shift and our intention to have our sales reps focus on that business. And you've seen what we've done since then. Seeing a really great growth in the hospital business. So, over time, what you should expect from us is a good balance between both. Both are important to us. There's different economics in both. We understand both. Clinically, again, we win in both. And we're taking share from the other 5 players in this space in both of those settings due to what Auryon brings scientifically, clinically, how it works, the safety, the effectiveness, the only product that can do in-stent restenosis treatment, work above the knee and below the knee.

So, we're really, really versatile for our customers. And that's really important to office-based labs and especially when they have economic challenges, space challenges and can't have a lot of other products on the shelf. And we're finding also some of those correlate in the hospital as well. So, great question, continue to follow us. You'll see growth continue in both of those care settings.

Unknown Analyst

And second question on what's driving NanoKnife, could you give us a sense of who is adopting as well right now? Is it mostly academic urology centers with an IRE champion? Or are you starting to see community urologists to come on board? And also related to that, when a site buys the generator, but takes a while to reach steady procedure volume, what's usually holding it back?

Stephen Trowbridge

Yes. So, starting on the first question, what's driving NanoKnife results these days is prostate. So, it's urologists and it's choosing NanoKnife to treat prostate. Prostate is by far the highest organ that is being treated. That flipped maybe a few handful of quarters ago. And there is a difference between when we used to be focused in the hepatobiliary side for pancreatic cancer, liver cancer and what we're seeing with physicians who are treating prostate cancer. The prostate cancer treatment is not something that is concentrated in the university settings. It is something that is being done in a lot of those regional hospitals and the other hospital setting. It's one of the reasons why we think it's a better business opportunity for us. There's an opportunity for us to get more systems out there to have more physicians doing it as opposed to being concentrated in some of those university settings.

So, we're seeing that through the prostate move, and that's what's driving NanoKnife as we go forward. And that's where our focus is going to be. We want to continue to drive NanoKnife utilization, particularly in the United States in prostate. Now in international markets, it's a little bit more balanced. We're seeing growth within prostate, but then there's also a lot of growth in utilization coming from folks who had done some of those liver and pancreatic treatments. NanoKnife is a great technology. There's opportunities for us in almost any solid tumor basis. But if you think about our strategy, we're focusing primarily in the U.S. on prostate and then supporting the use of NanoKnife as we think globally. And so we're excited about what we're seeing there. That's where the growth is coming from. On your question about what stops someone from really getting up utilization, it is a little bit specific to each individual physician.

For folks who are buying the system, that's a great sign that they're very committed to NanoKnife as part of their practice. One of the things we've also talked about, particularly in that urology setting is making sure that we've got alternative placement models so that we can get capital into the hands of physicians so they can start doing those procedures. I think what we're seeing is it's a lot of factors that go into physicians who are building up their business, starts with getting access to the capital, starts with what's best for the patient, right? And then they're choosing NanoKnife because they know that NanoKnife can avoid quality of life side effects and get to really good outcomes for their patients.

Last quarter, we talked about putting out our 2-year follow-up data coming out of PRESERVE being really excited about the fact that there were 0 additional incidents of recurrence coming out of NanoKnife. So, we know it's good for patients. They can get access to the capital, they can treat their patients and then get reimbursement. And that's why we've talked a lot about the work that we've done on reimbursement to provide that foundation for physicians. So, all those things working together are what helps drive a physician to really build their practice, and we like what we're seeing.

Operator

Ladies and gentlemen, that concludes our question-and-answer session. I'll turn the floor back to Mr. Clemmer for final comments.

James Clemmer

Thank you again for joining our call. We're really pleased with the start of our fiscal year for AngioDynamics. And what you heard here today is not an accident, it's not random. It's a well-planned idea that we could transform our company, starting with our portfolio changes we started to make 5 and 6 years ago. We were deliberate. We're intentional. We also tried to be very transparent with you on our journey, and you can see what we have today. So, today, we have a company built upon the strength of a medical device platform that gives us the capital and the strength and the background to invest in our Med Tech platform that will be the growth engine for years to come.

Today, what we've showed, I think, is that our products are winning in each of the markets that we serve, winning against really good companies and good competitors, but winning because we're getting confidence from the physicians that choose to use us to treat the patients they serve. The outcomes stand alone. So, we've got a really great company. We've got new people who joined us, brought their talents to our company and their ambition driven by their belief in what our mission is. I'm excited to welcome Eric to our company. And hopefully, you'll stay with our journey. We'll continue to deliver great results. Thank you again to all of my teammates in our company. Talk to you soon.

Operator

Thank you. This concludes today's conference call. You may disconnect your lines at this time. Thank you for your participation.